SecBot SecBot

COCP

Cocrystal Pharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001412486 Biotech & Drug Discovery
$0.9719 +0.02 (+2.31%)
Oct 26 4:00 PM ET · prev $0.9500
Market cap
$17.6M
Nano cap
Median target
🔒 Subscribers only
Next earnings
Nov 12
in 17 days · EPS est. −$0.17
1 year
−21.0%
from $1.23 · Oct 27
30 days
−19.7%
from $1.21
52-week range
$0.8200–1.57
−38% from high · low Jul 31
Avg volume 20D
40.8K
Oct 19 spike 152.3K
Short interest
175.2K
≈0.9% of shares · −45.7%
Days to cover
3.2
at average volume
Insider net
+$147.6K
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
10
analyzed by SecBot
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b norovirus challenge study…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $147.6K at an average $0.9525. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 3 added (0 new), 1 trimmed or exited.

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.175 → −$0.173 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −45.7% to 175.2K shares. 3.2 days to cover, ≈0.9% of shares.

  • TrendDOWNTREND

    13% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ROYAL BANK OF CANADANEAR_EXIT9—
VANGUARD CAPITAL MANAGEMENT LLCADD358,228$376.1K
RENAISSANCE TECHNOLOGIES LLCADD179,628$188.6K
JANE STREET GROUP, LLCDOUBLED25,761$27.0K
WELLS FARGO & COMPANY/MNDOUBLED7,039$7.1K
UBS Group AGDOUBLED4,644$4.7K
CITIGROUP INCNEAR_EXIT1$1.00
JANE STREET GROUP, LLCTRIM10,626$10.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2025

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Jun 20, 2025HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jan 22, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
May 14, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 4, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 20, 2024HC Wainwright & Co.
REITERATE
REITERATEBuy
Jan 3, 2024HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$147.6K
bought · 1 insider
$0
sold · 0 insiders
+2.0%
vs their $0.9525 cost
DateInsiderTypeValue
Aug 5, 2026
FROST PHILLIP MD ET AL
Director
BUY$9.8K
Aug 3, 2026
FROST PHILLIP MD ET AL
Director
BUY$70.6K
Jun 3, 2026
SAPIRSTEIN JAMES
Chief Executive Officer
AWARD235,000 sh
Feb 24, 2026
FROST PHILLIP MD ET AL
Director
BUY$20.0K
Feb 6, 2026
FROST PHILLIP MD ET AL
Director
BUY$47.3K

Earnings setup

Estimates
Nov 12
reports in 17 days
−$0.17
EPS estimate, this quarter
+1%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.17-$0.22–-$0.14-23.8%$0.00
Next Q-$0.15-$0.16–-$0.15-2.2%$0.00
Current FY-$0.72-$0.76–-$0.69-5.1%$110.0M
Next FY-$0.47-$0.58–-$0.37+18.1%$0.00

Short side

FINRA· Sep 30, 2026
175,246
shares short
-45.7%
vs prior settlement
3.2
days to cover
≈0.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 Clinical trial readout
Results Pending: CDI-988 (Phase 2) — Completed 38d ago
Trial: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults Af
Sep 9, 2026 SEC
Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b norovirus challenge study…
8-K — Impact 4/10
Aug 5, 2026 Insider
FROST PHILLIP MD ET AL bought 10,000 shares
Director @ $0.9816 ($9.8K)
Aug 3, 2026 SEC
Cocrystal Pharma entered into a $5M private placement with OPKO Health, selling 5,474,053 shares at $0.9134 per share…
8-K — Impact 5/10
Aug 3, 2026 Insider
FROST PHILLIP MD ET AL bought 75,000 shares
Director @ $0.9412 ($70.6K)
Jun 30, 2026 Inst.
ROYAL BANK OF CANADA — NEAR_EXIT
9 shares (—)
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — ADD
358,228 shares ($376.1K)
Jun 9, 2026 SEC
Cocrystal Pharma appointed James Sapirstein as CEO, replacing co-CEOs Sam Lee and James Martin, who remain as…
8-K — Impact 2/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
COCP Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 22, 2026
Trial readout
Results Pending: CDI-988 (Phase 2) — Completed 38d ago
Trial: A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus Sponsor…
Aug 17, 2026
Earnings date
COCP Q2 2026 Earnings Scheduled — 2026-08-17
Aug 12, 2026
Earnings date
COCP Q2 2026 Earnings Scheduled — 2026-08-12
Aug 3, 2026
Offering
Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health
Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026
May 18, 2026
Earnings date
COCP Q1 2026 Earnings Scheduled — 2026-05-18

SecBot reports

10 filings · 2 bullish · 1 bearish · 2 mixed · 5 neutral
All COCP filing & press-release reports (10)